Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HW243040 in Healthy Participants
NCT07737496Phase 1Recruiting
- Sponsor
- Hubei Bio-Pharmaceutical Industrial Technological Institute
- Start
- Aug 2026
- Primary completion
- May 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing HW243040 group with Placebo group (2 arms). Primary endpoint: Adverse Events. Started Aug 2026; status: recruiting.
02
Drugs
HW243040
Beyond the preview
Go deeper on NCT07737496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07737496.